Tratamiento para la infección latente por tuberculosis en niños: recomendaciones internacionales y para Colombia

Benjumea, Dione

doi:10.1016/s0123-9392(12)70008-5

Cited by 3 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…La forma más frecuente de TB extrapulmonar 33 reportada fue la ganglionar, en contraste con lo descrito en la literatura donde regularmente se reporta la TB pleural como la más frecuente 34,35 . En Colombia la información sobre las formas extrapulmonares predominantes en población infantil es limitada; no obstante, en una investigación realizada en un Hospital infantil de México (2016), la forma más frecuente de presentación extrapulmonar fue ganglionar 1 .…”

Section: Discussionunclassified

Situación epidemiológica de la Tuberculosis infantil en el departamento de Caldas 2016-2018

Caicedo-Cortés

Gallego-Henao³

et al. 2021

Infect

View full text Add to dashboard Cite

Objetivo: Describir la epidemiología de la tuberculosis infantil en el Departamento de Caldas (2016-2018). Materiales y métodos: Estudio observacional-descriptivo. Resultados: se registraron 41 casos (4%, 41/1.029). La incidencia fue 2,96/100.000 (2016), 6,31/100.000 (2017) y 4,34 /100.000 (2018). La mediana de edad fue 10 años (RI 2-16). El sexo femenino aporto 53,66%, predominó el estrato socioeconómico bajo (90,24%, 37/41), Manizales aportó la mayor carga de casos (43,9%, 18/41). La TB pulmonar se presentó en 39,02% de los casos de tuberculosis infantil. 68,29% (28/41) reportaron haber tenido síntomas alrededor de 15 días de evolución. 70,73% (29/41) presentarón tos con expectoración y 65,85% (27/41) reportaron astenia o disnea. La PPD se midió en 65,85% de la población (27/41) siendo positiva (> 10 mm) en 62,96% (17/27). El diagnóstico radiológico se realizó en 56,1% (23/41). Se reportaron 10 casos de TB extrapulmonar, la presentación más frecuente fue ganglionar (7/10). Se presentaron dos casos fatales. Discusión: La tuberculosis infantil en Caldas refleja la naturaleza de la enfermedad, afectándose principalmente niñas con vulnerabilidades sociales. El síntoma más común es tos húmeda con expectoración, similar a otros estudios desarrollados en Colombia. No se cuenta con una herramienta diagnostica con rendimiento suficiente, por lo que este sigue siendo un desafío clínico.

show abstract

Section: Discussionunclassified

Situación epidemiológica de la Tuberculosis infantil en el departamento de Caldas 2016-2018

Caicedo-Cortés

Gallego-Henao³

et al. 2021

Infect

View full text Add to dashboard Cite

show abstract

“…The qualitative approach allows us to understand the complexity that underlies the effectiveness of LTBI treatment. This can be summarized in three categories: daily life and conditions of possibility for children exposed to TB and their families (including forced migration); the Colombian health system does not guarantee real access to TB diagnosis and treatment; and perceptions and social constructions around TB (TB remains as a stigma) [ 24 ]. Considering these findings, the research team proposed the present protocol study addressing some of the issues aiming to tackle the treatment completion barriers by an integrated care strategy for children exposed to TB.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, social, psychological, and nutritional assistance will be provided, with a 12-month follow-up. The control group will be the historic 2015 to 2018 cohort who received the standard care protocol, with a 9-month scheme of isoniazid [ 24 ].…”

Section: Methodsmentioning

confidence: 99%

Implementation of an integrated care strategy for child contacts of tuberculosis patients: a quasi-experimental study protocol

et al. 2023

View full text Add to dashboard Cite

Background Childhood tuberculosis continues to be a major public health problem. Although the visibility of the epidemic in this population group has increased, further research is needed. Objective To design, implement and evaluate an integrated care strategy for children under five years old who are household contacts of bacteriologically confirmed pulmonary tuberculosis patients in Medellín and the Metropolitan Area. Methods A quasi-experimental study in which approximately 300 children who are household contacts of bacteriologically confirmed pulmonary tuberculosis patients from Medellín and the Metropolitan Area will be evaluated and recruited over one year. A subgroup of these children, estimated at 85, who require treatment for latent tuberculosis, will receive an integrated care strategy that includes: some modifications of the current standardized scheme in Colombia, with rifampicin treatment daily for four months, follow-up under the project scheme with nursing personnel, general practitioners, specialists, professionals from other disciplines such as social work, psychology, and nutritionist. Additionally, transportation and food assistance will be provided to encourage treatment compliance. This strategy will be compared with isoniazid treatment received by a cohort of children between 2015 and 2018 following the standardized scheme in the country. The study was approved by the CIB Research Ethics Committee and UPB. ClinicalTrials.gov identifier NCT04331262. Discussion This study is expected to contribute to the development of integrated care strategies for the treatment of latent tuberculosis in children. The results will have a direct impact on the management of childhood tuberculosis contributing to achieving the goals proposed by the World Health Organization's End TB Strategy. Trial registration ClinicalTrials.gov identifier NCT04331262. Implementation of an Integrated Care Strategy for Children Contacts of Patients with Tuberculosis. Registered 2 April 2020.

show abstract

Latent tuberculosis infection in patients with autoimmune diseases treated with Infliximab and Etanercept

Parra-Lara¹,

Ospina

Martínez

et al. 2019

Infect

View full text Add to dashboard Cite

Introduction: Latent tuberculosis infection (LTI) in patients receiving biological therapies is a reality, but this has not been studied in depth in Colombia. Objective: To determine the prevalence of LTI in patients with autoimmune diseases receiving treatment with Infliximab / Etanercept in a referral health center in Cali, Colombia, between the years 2011-2017. Methodology: A retrospective observational study was conducted. We reviewed the 'Registry of patients exposed to tumor necrosis factor-alpha (TNF-α) antagonist drugs in Fundación Valle del Lili'. Patients diagnosed with a chronic inflammatory disease were included who received treatment with Infliximab, Etanercept, or both and followed at least two years. Design: Retrospective observational study. We reviewed the 'Registry of patients exposed to tumor necrosis factor alpha (TNF-α) antagonist drugs in Fundación Valle del Lili'. Patients diagnosed with a chronic inflammatory disease were included who received treatment with Infliximab, Etanercept or both and followed at least a period of 2 years. Results: We included 82 patients; the median age was 47.5 years (IQR=28-60 years), 76% were female, 2% had intimate contact with tuberculosis, 15% were older than 65 years. The 56% had a diagnosis of rheumatoid arthritis as an indication of therapy, and 2% presented infection by hepatitis C virus. The median PPD was 12 mm (IQR=10-17 mm). The prevalence was 3.8% for LTI. Conclusion:The conversion to LTI shows an important prevalence, so it is convenient to perform a routine follow-up of patients receiving therapies with Infliximab and Etanercept.

show abstract

Tratamiento para la infección latente por tuberculosis en niños: recomendaciones internacionales y para Colombia

Cited by 3 publications

References 13 publications

Situación epidemiológica de la Tuberculosis infantil en el departamento de Caldas 2016-2018

Situación epidemiológica de la Tuberculosis infantil en el departamento de Caldas 2016-2018

Implementation of an integrated care strategy for child contacts of tuberculosis patients: a quasi-experimental study protocol

Latent tuberculosis infection in patients with autoimmune diseases treated with Infliximab and Etanercept

Contact Info

Product

Resources

About